Professor
Michael Hecht Olesen
Department of Endocrinology, Odense University Hospital
Projekt styring | ||
Projekt status | Sampling ongoing | |
Data indsamlingsdatoer | ||
Start | 01.07.2011 | |
Slut | 01.07.2021 | |
The main purpose of this multicenter interdisciplinary study is to improve our understanding of the complex mechanisms underlying the development of Cardiovascular Disease (CVD) in hypertension in order to improve prevention and treatment through more individualized and better targeted methods. These improvements will eventually give greater health for less money.
\nWe hypothesize that better description of risk factor exposure over time, taking into account new risk factors, risk factor interactions and genetic variations (individual susceptibility), can improve the prediction of subclinical cardiovascular target organ damage (TOD), changes in TOD and future CVD in patients with hypertension beyond that allowed by focusing only on traditional risk factors.
In approximately 30 European Society of Hypertension (ESH) Excellence Centers throughout Europe we will consecutively enroll 1.500 subjects aged 18-80 years with office blood pressure ? 140/90 mmHg or ongoing antihypertensive treatment. The subjects will be thoroughly investigated at inclusion and after one year of antihypertensive treatment following ESH guidelines and followed for five years. Subjects with known cancer, known life expectancy less than 1 year or inability to give written consent will be excluded.
Blood samples are taken and processed using local equipment. Blood samples for the biobank are stored at -80 degree Celsius and shipped to OPENs biobank.
\nIn all patients we will measure selected genetics, traditional risk factors (age, gender, smoking, blood pressure etc.), 24-hour blood pressure, home blood pressure, new biomarkers (Cystatin C, soluble urokinase plasminogen activator receptor, high sensitivity C-reactive protein, high sensitivity Troponin T, N-terminal pro brain natriuretic peptide) and different markers of TOD (urine albumin/creatinine ratio, left ventricular (LV) mass index, LV relative wall thickness, LV ejection fraction etc.). Proteomics in urine will be measured in subgroups characterized by not receiving antihypertensive treatment and having either marked TOD with very high or low risk based on SCORE or no TOD. Extra blood and urine samples will be kept for later analyzes.
Department of Endocrinology, Odense University Hospital
Istanbul University Cerrahpasa, School of Medicine, Turkey
Centre of Cardiology, North Estonia Medical Centre, Tallinn, Estonia
Department of Pharmacology, Hospital European Georges Pompidou, Paris, France
Department of Medical and Surgical Sciences, Clinic of Internal Medicine, University of Brescia, Italy
Clinica Medica, University of Milano-Bicocca, Ospedale San Gerardo, Italy
Department of Cardiology, S.Luca Hospital, Istituto Auxologico Italiano IRCCS, Milan & University of Milano-Bicocca, Italy
Internal Medicine, Hospital Clinico, University of Valencia, Spain
Medizinische Klinik, University Erlangen-Nuernberg, Germany
Department of Preventive Cardiology, Inst.Clin.Exp.Medicine, Prague, Czech Republic
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK
Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
Clinica Medica III, Policlinico Sant'Orsola Malpighi, Bologna, Italy
Centre for Clinical Pharmacology, Barts and the London Queen Mary's School of Medicine and Dentistry, London, UK
Vascular Risk Prevention Unit, Hospital Clínico, University of Barcelona, Spain
University of Ghent, Belgium
Emory University, Department of Cardiology, Asklepeion General Hospital, Athens, Greece
Division of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Department of Pharmacology and Toxicology, Universiteit Maastricht, Maastricht, Holland
University of Milan, Istituto Auxologico Italiano, Italy
Department of Hypertension and Diabetology, Medical University of Gdansk, Poland
Department of Clinical Sciences Medicine, University Hospital, Malmö, Sweden